Collectively, these observations indicate that HGF/MET signaling triggers a Pyk2-mediated mechanism of resistance to FGFR inhibitor that appears to be common in lung, gastric, and bladder cancer cells (Figure 6C). Here, MET is linked to urinary bladder cancer.